Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Nebuliser hygiene in cystic fibrosis: evidence-based recommendations

Jane Bell, Lauren Alexander, Jane Carson, Amanda Crossan, John McCaughan, Hazel Mills, Damian O'Neill, John E. Moore, B. Cherie Millar on behalf of the Northern Ireland Working Group on Nebuliser Care and Hygiene in Cystic Fibrosis
Breathe 2020 16: 190328; DOI: 10.1183/20734735.0328-2019
Jane Bell
1Northern Ireland Paediatric Cystic Fibrosis Centre, Dept of Physiotherapy, Royal Belfast Hospital for Sick Children, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Alexander
1Northern Ireland Paediatric Cystic Fibrosis Centre, Dept of Physiotherapy, Royal Belfast Hospital for Sick Children, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Carson
1Northern Ireland Paediatric Cystic Fibrosis Centre, Dept of Physiotherapy, Royal Belfast Hospital for Sick Children, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Crossan
2Northern Ireland Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John McCaughan
3Dept of Medical Microbiology, Royal Victoria Hospital, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hazel Mills
1Northern Ireland Paediatric Cystic Fibrosis Centre, Dept of Physiotherapy, Royal Belfast Hospital for Sick Children, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damian O'Neill
2Northern Ireland Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John E. Moore
2Northern Ireland Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
4Northern Ireland Public Health Laboratory, Dept of Bacteriology, Belfast City Hospital, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Cherie Millar
2Northern Ireland Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
4Northern Ireland Public Health Laboratory, Dept of Bacteriology, Belfast City Hospital, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bcmillar@niphl.dnet.co.uk
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Supplementary Materials
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Summary of recommendations as a flow diagram.

Tables

  • Figures
  • Supplementary Materials
  • Table 1

    Key terms and definitions

    TermDefinition
    AcquisitionIn the context of CF, an organism is acquired when it is first detected in a respiratory sample (e.g. sputum or cough swab)
    Active dryingIn relation to drying of nebulisers, this term means to proactively promote drying by physical means such as drying with a cloth or forced hot air by means of a fan (e.g. in the case of a dishwasher)
    AdherencePatients' compliance with the correct drug prescription and their individualised routines
    AerosolisedThe changing of a liquid medication into a mist that is subsequently delivered to the lungs by an appropriate device (e.g. nebuliser)
    Air dryingLeaving respiratory devices including nebulisers to passively dry in air
    Aseptic techniqueSterile manipulation to minimise risk of contamination
    AntibioticA substance that acts specifically to kill bacteria (bactericidal) or to inhibit growth of bacteria (bacteriostatic)
    Ideally, the antibiotic should have minimal action on human cells
    Antibiotics are chosen to target different classes of bacteria and the various antibiotic groups act on the bacteria in different ways
    Antibiotics may be delivered orally, by injection into a muscle or vein or nebulised via the airways
    AntifungalA substance designed to kill or inhibit the growth of fungi
    BiofilmWhen microorganisms grow attached to a surface, they may produce a charged extracellular matrix with a high water content composed of polysaccharides and protein
    The resultant biofilm can protect the organisms from the normal host defence mechanisms and, since the components are polar in nature, the matrix may be impenetrable to antibiotics
    In mature biofilm, the oxygen tension may be low, allowing the growth of a mixed population of aerobic and anaerobic bacteria
    Such biofilm in the lumen of the bronchi in the CF lung may be the source of a periodic surge of bacteria in the airways precipitating a pulmonary exacerbation requiring intravenous antibiotic treatment
    Burkholderia cenocepaciaB. cenocepacia is Gram-negative bacterium responsible for chronic respiratory disease in CF patients
    Burkholderia cepacia complexA group of ≥20 closely related bacterial species, many of which have been associated in the pathology of lung disease in CF patients
    The most important members of this complex include B. cenocepacia, B. multivorans and B. vietnamiensis
    COPDA lung disease characterised by chronic obstruction of lung airflow that interferes with normal breathing and is not fully reversible
    ColonisationPhysical persistence of microorganisms in the airways, even in the presence of antibiotics
    This can subsequently lead to a state of chronic colonisation when a microorganism can be repeatedly detected in specimen from a body site
    Chronic colonisation may be marked by the finding of “mucoid” colonies of Pseudomonas aeruginosa or slow-growing “small-colony variants” of Staphylococcus aureus and such organisms may be impossible to eradicate using antibiotics
    In CF, chronic colonisation of the lungs by such organisms is usually associated with a clinical deterioration
    CompressorThis is a device that compresses room air and forces it, by increased pressure and at a high velocity, through a liquid medicine to turn it into a mist of fine droplets which is then inhaled via a nebuliser
    ContaminationThe addition of microorganisms from the environment, other patients, healthcare workers or the patients themselves to a surface or object that did not previously contain such organisms
    DetergentA chemical that solubilises soil and dirt and helps clean (e.g. dishwashing liquid)
    Detergents generally have no antibacterial properties, unless antibacterial substances are specifically incorporated into their formulation and are marketed accordingly
    DisinfectantA chemical that is antimicrobial (e.g. chlorine tablets) and destroys vegetative forms of harmful microorganisms at the proper concentration (e.g. bacteria and fungi), especially on inanimate objects, but which may be less effective in destroying spores
    DisinfectionThe process (chemical, heat, ozone or ultraviolet light) by which a high percentage of the microorganisms are removed or killed from an object or surface
    This process will not inactivate bacterial/fungal spores and is less effective than sterilisation
    Distilled waterWater that has been purified through boiling/evaporation and allowed to condense back into a liquid, thus removing many impurities
    Environmental organismBacteria or fungi commonly detected from soil or water sources
    Although such organisms are often highly resistant to antibiotics, they are not usually included in the panel of clinically significant pathogens and not the target of bacterial culture in the clinical laboratory
    They do not usually colonise and cause infection except when there is a breach in the normal body defence against microorganisms
    In the CF lung, the proper function of the ciliary epithelium is compromised and CF patients are subject to colonisation by a succession of environmental bacteria and fungi
    To detect such organisms, extra resources are used by the clinical bacteriology laboratory processing CF respiratory samples
    EradicationAfter the initial acquisition of certain bacteria, concerted attempts are made to eliminate the bacteria, usually by means of repeated courses of antibiotics
    Early detection is the key to successful elimination and ideally, the treatment should be commenced as soon as possible after the organism is detected
    The declaration that a patient has been cleared of an organism is always retrospective and requires a period (e.g. 1 year) during which only negative samples are obtained
    Evidence-based practice (EBP)The conscientious, explicit and judicious use of current best evidence in making decisions about the care of patients
    EBP integrates best available external clinical evidence from systematic research
    MicrobiomeThe sum of all the organisms in a region of the body
    Using molecular methods including PCR and genetic sequencing, hundreds of groups may be identified
    Studies of the microbiome in respiratory samples from CF patients show dynamic diversity of bacterial species
    When chronic colonisation occurs, species diversity decreases with high concentrations of the relatively few organisms, such as P. aeruginosa or B. cepacia
    Mucociliary clearanceThe removal of particles from the airways as the result of the movement of mucus due to the beating of the underlying cilia
    NebulisedAdministering a drug to the airways or lungs in the form of an aerosolised mist of fine droplets
    NebuliserA device that delivers aerosol droplets suitable for patient inhalation
    Adaptive Aerosol DeliverySmall, quick devices that give improved deposition of medications by delivering an aerosol on inhalation during the individual’s breathing cycle (e.g. I-neb; Philips Respironics, Murrysville, PA, USA)
    Disposable nebuliserDiscarded every 24 h
    Jet nebuliserCompressed air or oxygen used to aerosolise liquid medications
    Reusable nebuliserCan be used more than once
    Vibrating mesh nebuliserMoves liquid medication through a metal mesh to break up into a mist where each drop is a similar size, delivering a mist of medication constantly (e.g. E-flow; Pari, Byfleet, UK)
    NonpathogensOrganisms that do not cause disease, harm or death
    Nosocomial infectionA hospital-acquired infection
    Opportunistic organismsOrganisms that take advantage of certain opportunities to cause disease (e.g. a weakened immune system)
    Pathogens/pathogenic organismsDisease causing microorganisms, such as bacteria, fungi and viruses
    Pseudomonas aeruginosaA Gram-negative bacterium, commonly found in the environment, which is a significant pathogen in patients with CF
    Potable waterDrinking water
    Pulmonary exacerbationAn increase in respiratory symptoms (e.g. increased cough, sputum production or shortness of breath) accompanied by an acute decrease in lung function
    Pulmonary infectionWorsening clinical symptoms or signs, caused by pathogens identified in respiratory secretion samples
    Source/reservoir of infectionThe principal habitat in which a specific infectious agent lives and multiplies
    The reservoir is necessary for the infectious agent either to survive or to multiply in sufficient amount to be transmitted to a susceptible host
    Stenotrophomonas maltophiliaA Gram-negative bacterium identified in people with CF
    Although its clinical significance is a matter of debate, it is sometimes seen persistently in combination with other more significant pathogens such as P. aeruginosa or S. aureus
    In a few cases, this bacterium is the sole culminating organism in a CF patient with chronic pulmonary infection
    SterilisationThe process by which all microorganisms, including bacterial and fungal spores, are destroyed
    Sterile waterWater is sterilised when it has been treated to destroy all microorganisms including bacterial and fungal spores
    TransmissionThe process of passing microorganisms from one person or place to another
  • Table 2

    Organisms which have been recovered from the nebulisers of patients with CF[10–22]

    Gram-negative bacteriaAchromobacter xylosoxidans
    Acinetobacter spp. (A. johnsonii, A. junii)
    Aeromonas hydrophila
    Burkholderia cepacia complex
    Chryseobacterium indologenes
    Comamonas spp. (C. acidovorans, C. testosteroni)
    Delftia spp.
    Enterobacter spp.
    Escherichia coli
    Flavobacterium spp. (F. indologenes, F. meningosepticum)
    Haemophilus parahaemolyticus
    Klebsiella spp. (K. ozaenae, K. pneumoniae)
    Moraxella spp. (M. osloensis)
    Neisseria subflava
    Ochrobactrum anthropi
    Oligella urethralis
    Pantoea agglomerans
    Proteus spp.
    Pseudomonas spp. (P. aeruginosa, P. aureofaciens, P. fluorescens. P. stuzeri, P. vesicularis)
    Rhizobium (Agrobacterium) radiobacter
    Serratia marcescens
    Shewanella putrefaciens
    Sphingobacterium spp. (Sphingomonas paucimobilis)
    Stenotrophomonas maltophilia
    Gram-positive bacteriaActinomyces viscosus
    Bacillus spp.
    Corynebacterium spp.
    Enterococcus faecalis
    Granulicatella adiacens
    Microbacterium spp. (M. oxydans, M. paraoxydans)
    Micrococcus spp. (M. luteus, M. lylae)
    Rothia spp. (R. dentocariosa, R. mucilaginosa)
    Staphylococcus spp. (S. aureus (MRSA, MSSA), S. epidermidis, S.saprophyticus, S. pasteuri)
    Streptococcus spp. (viridans group streptococci)
    Other bacteriaPaenibacillus spp.
    YeastsCandida spp. (C. albicans, C. guilliermondii, C. holmii, C. krusei, C. lipolytica, C. parapsilosis, C. sake, C. zeylanoides)
    Cryptococcus spp. (C. albidus, C. carnescens, C. unigutatulus)
    Filamentous fungiAspergillus spp. (A. fumigatus, A niger, A. versicolor)
    Aureobasidium pullulans
    Cladosporium spp. (Cladosporium sphaerospermum)
    Exophiala spp. (E. jeanselmei, E. oligosperumum)
    Lecanicillium spp. (L. lecanii)
    Microsporum fulvum
    Myxotrichum sp.
    Penicillium spp. (P. commune, P. coryphilum, P. digitatum P. glabrum, P. griseofulvin)
    Rhizopus oryzae
    Rhodotorula spp. (R. glutinis, R. minuta, R. mucilaginosa)
    Scopulariopsis chartarum
    Ulocladium chartarum
    Sporobolomyces roseus
    Trichosporon asahii

    MRSA: methicillin-resistant S. aureus; MSSA: methicillin-sensitive S. aureus.

    • Table 3

      A list of documented methods used to disinfect nebulisers

      MethodEvidence
      Chemical methods
       Acetic acid/vinegar
      • Ineffective against CF pathogens such as B. cenocepacia, S. aureus and MRSA [52]

       Benzyl ammonium chloride (Control III; Maril Inc., Tustin, CA, USA)
      • Not recommended due to narrow spectrum of activity and slow action [26]

       Ethyl alcohol/ethanol (70%)
      • Has been reported to reduce fungal and bacterial contamination of nebulisers but not completely [53]

       Isopropyl alcohol/propanol (70%)
      • Will lose activity over time; therefore, needs to be regularly replaced

        Saliva and sputa may protect microorganisms from the action of alcohol; therefore, prior washing of devices is required

        May be ineffective against mycobacteria [54]

        It has been reported that isopropyl alcohol disinfection does not affect nebuliser output[55]

       Hydrogen peroxide (3%)
      • Although listed in the CFF-IP&C guidelines (3% hydrogen peroxide for 30 min), there is limited evidence supporting disinfection of nebulisers with hydrogen peroxide [26]

       Sodium hypochlorite
      • Although hypochlorite disinfection has been shown to decrease the contamination of nebulisers due to commensal and environmental organisms, a similar reduction has not been observed in the case of CF pathogens [10, 56]

        Corrosive chemicals such as hypochlorite are prohibited for disinfecting the mesh membrane of the e-Flow rapid nebuliser [5]

       Ozone
      • Commercially available SoClean (Peterborough, NH, USA) ozone machine has been examined with type strains of B. cepacia, P. aeruginosa, S. aureus and S. maltophilia

        Preliminary findings have shown a 5-min infusion followed by a 120-min dwell time to be effective against these organisms when spiked onto a Pari LCPlus nebuliser, without affecting nebuliser output

        Further investigation is required in relation to nontuberculous mycobacteria and clinical strains of CF pathogens [57]

       Squalamine
      • Squalamine (a steroid–polyamine conjugate compound with broad spectrum antimicrobial activity) targets membrane integrity, and has potential to reduce levels of S. aureus, P. aeruginosa, Candida albicans and Aspergillus niger on contaminated nebulisers [58]

        Further work needs to be completed prior to advocating the employment of this molecule

      Heat methods
       Boiling (continuous boil in water for 5 mins)
      • The CFF-IP&C guidelines and manufacturers’ guidelines recommend that nebulisers should be disinfected by placing them in boiling water for 5 mins [26]

        Decrease in nebuliser output with Pari LC Plus® device following repeated disinfection by boiling [55]; however, experimental limitations must be considered [59]

       Steam (electric baby bottle steam disinfectors)
      • See table 4

       Steam (microwave) (place in microwave-safe receptacle submerged in water and microwave for 5 mins, 2.45 GHz)
      • Evidence in CFF-IP&C guideline taken from [65–67]; none of these studies employed nebulisers

        This method cannot be used with nebulisers that contain metal components (e.g. mesh in the eFlow rapid)

        Dutch study demonstrated that nebulisers contaminated with Enterococcus faecalis, S. aureus and P. aeruginosa were free of microorganisms after microwave treatment (650 W, 9 min) [68]

       Dishwasher disinfection (≥70°C/158°F for 30 min)
      • Although listed in the CFF-IP&C guidelines [26], there is limited evidence supporting disinfection of nebulisers using high-temperature dishwashers

       Autoclave (a maximum of 277°F or 136°C)
      • Certain nebuliser parts may be sterilised using autoclave methods (e.g. Pari Reusable Nebuliser parts, except mask and tubing) [69]

      MRSA: methicillin-resistant S. aureus.

      • Table 4

        Advantages and disadvantages of steam disinfection for nebuliser devices

        AdvantagesDisadvantages
        • Effective killing of a wide range of bacterial pathogens [60–62], including:

          B. cepacia complex

          B. cepacia

          Burkholderia multivorans

          Candida albicans

          Enterococcus faecium

          Haemophilus influenzae

          Mycobacterium abscessus abscessus

          Mycobacterium abscessus bolletii

          Mycobacterium abscessus massiliense

          Mycobacterium abscessus/chelonae

          Mycobacterium avium intracellulare

          Mycobacterium chelonae

          P. aeruginosa (mucoid, nonmucoid)

          S. aureus (MRSA, MSSA)

          Steno. maltophilia

        • Apart from the Wabi Baby disinfector, all other baby bottle disinfector manufacturers have not endorsed their product for nebuliser disinfection

        • None of the steam disinfector units have indicators to show/confirm that unit has successfully completed its full cycle

        • The commercial Steam Sterilizer Plus Model (Wabi Baby, Frisco, TX, USA) has been examined for its effectiveness in disinfecting nebulisers spiked with CF organisms [63]:

          Achromobacter xylosoxidans

          B. cepacia

          P. aeruginosa

          MSSA

        • P. aeruginosa (mucoid, nonmucoid) and nontuberculous mycobacteria were not detected in either wet or dry fully assembled nebulisers following steam disinfection even in the presence of sputa [62]

        • Different brands of steam disinfectors performed effectively [62]

        • Terminal (end-stage) disinfection will allow for destruction of above pathogens, which may enter during prior stages (tap water, residual sputum, detergent, handling, etc.)

        • Relatively cheap (approximately GBP 50, EUR 80, USD 70)

        • Widely available in electrical shops and from online sellers

        • Wabi Baby device only available in USA

        • Simple to operate

        • No consumable items required, except tap water

        • Fast cycle speeds (approximately 8–15 min to disinfection)

        • Disinfected nebuliser can be stored in disinfector units post-cycle until required (≤24 h), thus avoiding post-disinfection contamination from surfaces, hands, environment, tap water

        • Portable (maybe taken on holiday/travel if voltage compatible)

        • Voltage compatibility in different countries

        Can be used with metal components (e.g. metal vibrating mesh)
        • No membrane performance effect with Pari e-Flow rapid device [64]

        • Decrease in nebuliser output with Pari LC Plus device following repeated steam disinfection [55]; however, experimental limitations must be considered [59]

        MRSA: methicillin-resistant S. aureus; MSSA: methicillin-sensitive S. aureus.

        • Table 5

          Summary of evidence-based best practice guidelines relating to nebuliser hygiene in CF

          New nebuliser parts should be washed and disinfected before first use (recommendation 2)
          During hospital admission and at home, wash the nebuliser parts after each use (recommendation 3)
          Nebulisers should be washed and re-disinfected immediately prior to use after greater than 24 h of inactivity (recommendation 4)
          At-home recommendationsInpatient recommendations
          Wash hands thoroughly with soap and water and use hand disinfector gel before starting the cleaning process (Recommendation 1)Wash hands thoroughly with soap and water and use hand disinfector gel before starting the cleaning process.
          Gloves should be worn by healthcare professionals with hand hygiene performed after removal of gloves (recommendation 1)
          Disconnect nebuliser from the compressor unit and dissemble into constituent components (recommendation 11)Disconnect nebuliser from the compressor unit and dissemble into constituent components (recommendation 11)
          Washing
           Wash nebuliser components in a solution of warm tap water (recommendation 12) and dishwashing liquid in accordance with the detergent manufacturer's guidance (recommendation 14)
          Washing
           Wash nebuliser components in a solution of warm tap water (recommendation 12) and dishwashing liquid in accordance with the detergent manufacturer's guidance (recommendation 14)
          Location
           Do not wash nebuliser parts directly in kitchen or bathroom sinks (recommendation 8) or the dishwasher (recommendation 9)
           This should be done in a dedicated plastic, glass or metal bowl in the patients' kitchen (recommendation 10)
          Location
           This should be done in a disposable bowl, metal bowl or basin (not directly in a sink; recommendation 5) in the patients' room (recommendation 6)
          Rinsing
           Sterile water must be used during a final rinse when immediate disinfection is not possible (recommendation 13)
          Rinsing
           Sterile water must be used during a final rinse, when immediate disinfection is not possible (recommendation 13).
          Disposal of waste water
           Disposal of waste water should be via the toilet, ensuring the toilet lid is closed prior to flushing (recommendation 17)
          Disposal of waste water
           Metal bowl and waste water should be sent to the ward sluice (recommendation 15).
           Waste water should be disposed of here and the metal bowl should be sterilised by autoclaving (Recommendation 16).
          Disinfection
           Washed and rinsed nebulisers should be disinfected after each use (recommendation 7) using an electric baby bottle steam disinfector, (recommendation 18)
          Disinfection
           Washed and rinsed nebulisers should be disinfected immediately after each use (recommendation 7) using an electric baby bottle steam disinfector (recommendation 18), or
           reusable nebulisers may be autoclaved, where the nebuliser manufacturer states that the device can be safely autoclaved (recommendation 19)
          Storage
           Leave the disinfected nebuliser parts undisturbed in the disinfector until the next use (within 24 h)
           Should the parts be disturbed (i.e. lid lifted off for any reason) then the disinfection process should be repeated and the parts left undisturbed until the next use (within 24 h) (recommendation 20)
          Storage
           Leave the disinfected nebuliser parts undisturbed in the disinfector until the next use (within 24 h)
           Should the parts be disturbed (i.e. lid lifted off for any reason) then the disinfection process should be repeated and the parts left undisturbed until the next use (within 24 h) (recommendation 20)
          After disinfection
           Wash hands thoroughly with soap and water, and use hand disinfector gel after the cleaning and disinfection process prior to reassembling the nebuliser device (recommendation 1)
          After disinfection
           Wash hands thoroughly with soap and water, and use hand disinfector gel after the cleaning and disinfection process prior to reassembling the nebuliser device (recommendation 1)

        Supplementary Materials

        • Figures
        • Tables
        • Supplementary Material

          Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

          Figure S1 EDU-0328-2019.figureS1

          Table S1 EDU-0328-2019.tableS1

          Table S2 EDU-0328-2019.tableS2

        PreviousNext
        Back to top
        Vol 16 Issue 2 Table of Contents
        Breathe: 16 (2)
        • Table of Contents
        • Index by author
        Email

        Thank you for your interest in spreading the word on European Respiratory Society .

        NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

        Enter multiple addresses on separate lines or separate them with commas.
        Nebuliser hygiene in cystic fibrosis: evidence-based recommendations
        (Your Name) has sent you a message from European Respiratory Society
        (Your Name) thought you would like to see the European Respiratory Society web site.
        CAPTCHA
        This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
        Print
        Citation Tools
        Nebuliser hygiene in cystic fibrosis: evidence-based recommendations
        Jane Bell, Lauren Alexander, Jane Carson, Amanda Crossan, John McCaughan, Hazel Mills, Damian O'Neill, John E. Moore, B. Cherie Millar
        Breathe Jun 2020, 16 (2) 190328; DOI: 10.1183/20734735.0328-2019

        Citation Manager Formats

        • BibTeX
        • Bookends
        • EasyBib
        • EndNote (tagged)
        • EndNote 8 (xml)
        • Medlars
        • Mendeley
        • Papers
        • RefWorks Tagged
        • Ref Manager
        • RIS
        • Zotero

        Share
        Nebuliser hygiene in cystic fibrosis: evidence-based recommendations
        Jane Bell, Lauren Alexander, Jane Carson, Amanda Crossan, John McCaughan, Hazel Mills, Damian O'Neill, John E. Moore, B. Cherie Millar
        Breathe Jun 2020, 16 (2) 190328; DOI: 10.1183/20734735.0328-2019
        del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
        Full Text (PDF)

        Jump To

        • Article
          • Abstract
          • Abstract
          • Sources of information
          • Definitions of key terms
          • Why is there a need to clean and disinfect nebulisers?
          • Experiences of nebuliser hygiene at home
          • Evidence-based guidance
          • Disposal of used water
          • Disinfection procedures
          • Drying
          • Storage
          • Barriers and motivators related to nebuliser hygiene
          • Conclusions
          • Supplementary material
          • Acknowledgements
          • Footnotes
          • References
        • Figures & Data
        • Info & Metrics
        • PDF

        Subjects

        • CF and non-CF bronchiectasis
        • Tweet Widget
        • Facebook Like
        • Google Plus One

        More in this TOC Section

        • Idiopathic pulmonary fibrosis and lung cancer
        • Diagnosis and management of PH related to chronic respiratory disease
        • Pulmonary renal syndrome: a clinical review
        Show more Reviews

        Related Articles

        Navigate

        • Home
        • Current issue
        • Archive

        About Breathe

        • Journal information
        • Editorial board
        • Press
        • Permissions and reprints
        • Advertising

        The European Respiratory Society

        • Society home
        • myERS
        • Privacy policy
        • Accessibility

        ERS publications

        • European Respiratory Journal
        • ERJ Open Research
        • European Respiratory Review
        • Breathe
        • ERS books online
        • ERS Bookshop

        Help

        • Feedback

        For authors

        • Intructions for authors
        • Publication ethics and malpractice
        • Submit a manuscript

        For readers

        • Alerts
        • Subjects
        • RSS

        Subscriptions

        • Accessing the ERS publications

        Contact us

        European Respiratory Society
        442 Glossop Road
        Sheffield S10 2PX
        United Kingdom
        Tel: +44 114 2672860
        Email: journals@ersnet.org

        ISSN

        Print ISSN: 1810-6838
        Online ISSN: 2073-4735

        Copyright © 2023 by the European Respiratory Society